{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-008163","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.878714+00:00","generated_at":"2026-06-19T01:28:18.024293+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Insmed reports Q4 2022 ARIKAYCE revenue $59.3M, full year $245.4M; net loss $1.21 per share","bullets":["ARIKAYCE global revenue grew 30% in 2022 to $245.4M; Q4 revenue $59.3M, impacted by $7.5M French pricing adjustment.","Net loss for Q4 2022 was $160.1M ($1.21/share) vs $113.0M ($0.95/share) in Q4 2021; full year net loss $481.5M ($3.91/share).","Phase 3 ASPEN trial of brensocatib in bronchiectasis completed adult patient screening; topline data expected Q2 2024.","Company guides 2023 ARIKAYCE global revenue $285-300M; cash position $1.15B as of Dec 31, 2022.","ARISE study topline data expected Q3 2023; ENCORE enrollment by end 2023; early-stage research update May 8, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-008163","json":"https://secwatch.observer/filing/0001140361-23-008163.json","markdown":"https://secwatch.observer/filing/0001140361-23-008163.md","text":"https://secwatch.observer/filing/0001140361-23-008163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036123008163/0001140361-23-008163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036123008163/brhc10048554_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T01:28:18.024293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efb0287836020eb08da74dc584422fbc06780505","claim":"INSMED Inc reported the fourth quarter ended December 31, 2022 results: revenue $59.3 million, net income net loss of $160.1 million, EPS $1.21 per share.","evidence_excerpt":"on Track to Share Topline Data from Post-Marketing ARISE Study of ARIKAYCE ® (amikacin liposome inhalation suspension) in Third Quarter of 2023— —ARIKAYCE Total Revenue of $59.3 Million for the Fourth Quarter and $245.4 Million for the Full Year 2022, Reflecting 30% Annual Growth— BRIDGEWATER, N.J., February 23, 2023 /PRNewswire/ — Insmed Incorporated","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036123008163/0001140361-23-008163-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$59.3 million"},{"label":"Net income","value":"net loss of $160.1 million"},{"label":"EPS","value":"$1.21 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"feabf8c2bba054b8c7114b13f03696cd6885656f","claim":"INSMED Inc reported the full year ended December 31, 2022 results: revenue $245.4 million, net income net loss of $481.5 mill.","evidence_excerpt":"Total revenue for the full year 2022 was $245.4 million, compared to total revenue of $188.5 million for the full year 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036123008163/0001140361-23-008163-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$245.4 million"},{"label":"Net income","value":"net loss of $481.5 mill"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}